Abstract 1552O
Background
CIPN is a common, dose-limiting side effect of taxane-based chemotherapy. Currently there is no established strategy for prevention or treatment. Smaller studies suggest that cooling or compression could have a preventive effect. In this randomized trial we investigated the effectiveness of one-sided hand-cooling or compression for the prevention of CIPN.
Methods
122 breast cancer patients who received weekly (nab-)paclitaxel-based (neo-)adjuvant chemotherapy were 1:1 randomized to either cooling or compression of the dominant hand. No intervention was performed on the other hand. Cooling was performed with a frozen glove (Elasto-Gel; 84400APT Cedex, Akromed), compression was applied by two surgical gloves (one size smaller than tight-fitting size) 30 minutes before, during and 30 minutes after taxane therapy. The primary endpoint was efficacy to prevent grade ≥2 sensory polyneuropathy evaluated by Common Terminology Criteria for Adverse Events v4.0 (CTCAE). In a second hierarchical test, CIPN rates between both intervention groups were compared. CIPN was further assessed by the Total Neuropathy Score (TNSc), patient self-report questionnaires (EORTC-QLQ-CIPN20), MR-neurography (n=21) and nerve conduction studies. Additionally, we evaluated onycholysis, skin toxicity, quality of life, CIPN-associated dose-reductions, treatment discontinuations and potential risk factors.
Results
Cooling and compression were highly effective in preventing grade ≥2 CIPN (cooling: 25 vs. 46%; p-value=0.0008; compression: 23 vs. 39%; p-value=0.0016) with similar efficacy (no significant difference was found: p-value=0.7303). MR-neurography was highly sensitive for detecting CIPN showing increased T2 nerve-to-muscle signal ratio indicating edematous nerve changes. Updated results will be presented.
Conclusions
POLAR is the first trial to compare cooling and compression for preventing CIPN. Both interventions were highly effective and almost halved the risk of grade ≥2 CIPN. These findings could play an important role beyond gynecological oncology.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Intramural funding as part of the elevator pitch of the National Center for Tumor Diseases (NCT) Heidelberg.
Disclosure
L. Michel: Non-Financial Interests, Personal and Institutional, Advisory Board: German Breast Group (GBG); Financial Interests, Personal, Invited Speaker: Pfizer, Roche, Eisai, AstraZeneca, Lilly, MSD; Financial Interests, Personal, Advisory Role: Pfizer; Financial Interests, Personal, Funding: Pfizer. K. Smetanay: Financial Interests, Personal, Invited Speaker: Celgene, Roche, AstraZeneca, MSD, Novartis, Lilly; Financial Interests, Personal, Advisory Board: MSD. C. Fremd: Financial Interests, Personal, Invited Speaker: Celgene, Pfizer, Novartis, Amgen, AstraZeneca, EISAI, Lilly; Financial Interests, Personal, Funding: Pfizer. D. Jäger: Financial Interests, Personal, Advisory Role: CureVac AG, Definiens, F. Hoffmann-La Roche Ltd, Genmab A-S, Life Science Inkubator GmbH, VAXIMM AG, OncoOne Research & Development Research GmbH, Oncolytics Biotech Inc, BMS Stiftung Immunonkologie; Financial Interests, Personal, Writing Engagements: Terrapinn, Touch Medical Media, BMS GmbH & Co KGaA; Financial Interests, Personal, Sponsor/Funding: Amgen Inc, Oryx GmbH, Roche Glycart AG, Parcel.com, BMS, IKTZ HD GmbH; Financial Interests, Personal, Advisory Board: CureVac, Definiens, Hoffmann-La Roche, Genmab A-S, Life Science Inkubator GmbH, Vaximm AG, Oncolytics Biotech Inc. F. Marmé: Financial Interests, Personal, Invited Speaker: AstraZeneca, Tesaro, Pfizer, PharmaMar, Eisai, MSD, celgene , Lilly, Pierre-Fabre, Vaccibody, Seagen, Immunomedics, Janssen-Cilag, Myriad, Curevac; Financial Interests, Personal, Sponsor/Funding: Clovis, GenomicHealth. A. Schneeweiss: Financial Interests, Personal, Invited Speaker: Celgene, Roche, Abbvie, Pfizer, AstraZeneca, Novartis, MSD, Tesaro, Lilly, GSK, Seagen, Gilead, Pierre Fabre, onkowissen.de; Financial Interests, Personal, Funding: Molecular Partner, Roche, Pfizer; Financial Interests, , Invited Speaker: Metaplan. All other authors have declared no conflicts of interest.
Resources from the same session
1551O - Factors associated with chemotherapy (CT)-related amenorrhea (CRA) and its relationship with quality of life (QOL) in premenopausal women with early breast cancer (BC): Results from the prospective CANTO cohort study
Presenter: Rayan Kabirian
Session: Proffered Paper session: Supportive and palliative care
Resources:
Abstract
Slides
Webcast
1263O - Evaluation of weight gain and overall survival of male vs. female patients with advanced non-small cell lung cancer (NSCLC) receiving first-line chemotherapy
Presenter: Eric Roeland
Session: Proffered Paper session: Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Invited Discussant 1551O and 1263O
Presenter: Karin Jordan
Session: Proffered Paper session: Supportive and palliative care
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Supportive and palliative care
Resources:
Slides
Webcast
1553O - Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)
Presenter: Aditya Bardia
Session: Proffered Paper session: Supportive and palliative care
Resources:
Abstract
Slides
Webcast
217O - Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC)
Presenter: Naoto Ueno
Session: Proffered Paper session: Supportive and palliative care
Resources:
Abstract
Slides
Webcast
Invited Discussant 1552O, 1553O and 217O
Presenter: Galina Velikova
Session: Proffered Paper session: Supportive and palliative care
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session: Supportive and palliative care
Resources:
Slides
Webcast